https://www.live-feeds.com/feed/an-experimental-single-time-treatment-slashed-cholesterol-for-a-yearContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/an-experimental-single-time-treatment-slashed-cholesterol-for-a-yearhttps://www.live-feeds.com/feed/an-experimental-single-time-treatment-slashed-cholesterol-for-a-year#u54043Tue, 01 Sep 2026 13:31:16 +0000CRISPR Therapeutics' CTX310, a single-time gene-editing treatment targeting the ANGPTL3 gene, has shown to safely and continuously lower cholesterol and triglycerides for one year in a Phase 1a trial. This approach aims to provide a permanent solution for high cholesterol by editing a specific gene, eliminating the need for daily medication. The treatment has yielded promising results, prompting the company to pursue the highest dose of the lipid-lowering treatment.Why it mattersHigh cholesterol is a significant risk factor for cardiovascular disease, which is a leading cause of death wor https://www.live-feeds.com/feed/an-experimental-single-time-treatment-slashed-cholesterol-for-a-yearhttps://www.live-feeds.com/feed/an-experimental-single-time-treatment-slashed-cholesterol-for-a-year#u52516Sun, 30 Aug 2026 14:50:36 +0000CRISPR Therapeutics reported Phase 1a trial data for CTX310, a single-time gene-editing treatment that safely and continuously lowered cholesterol and triglycerides for one year. The therapy targets the ANGPTL3 gene to provide deep and durable editing. Following these promising results presented at the ESC Congress 2026, CRISPR Therapeutics intends to pursue the highest dose of the lipid-lowering treatment. This approach aims to eliminate high cholesterol permanently by snipping a specific gene rather than relying on daily or periodic medication.Why it mattersTraditional cholesterol management